Navigation Links
Vermillion Announces Appointment of John Hamilton to Board of Directors
Date:4/10/2008

FREMONT, Calif., April 10 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced the appointment of John F. Hamilton to its board of directors. Mr. Hamilton is the former vice president and chief financial officer of Depomed, Inc., a specialty pharmaceutical company.

"John brings more than 20 years of active board-level engagement on financial, strategic and audit matters to Vermillion. His solid experience working with small to mid-size companies in the healthcare sector is a perfect fit with our business model," said Gail Page, President and CEO of Vermillion. "We are pleased to welcome John to the board, especially at such an exciting time in the company's evolution as we prepare to commercialize several of our diagnostic tests later this year. His financial savvy and analytical approach will prove invaluable to the Company."

Mr. Hamilton began his career in the banking industry and went on to hold senior financial positions at several biopharmaceutical companies including Glyko, Inc. -- now BioMarin Pharmaceuticals -- and Chiron Corporation. He sits on the regional board of directors of the Association of Bioscience Financial Officers and is past-president of the Treasurers Club of San Francisco. Mr. Hamilton received his M.B.A. from the University of Chicago and his B.A. in International Relations from the University of Pennsylvania.

Mr. Hamilton's appointment to Vermillion's board of directors went into effect on April 9, 2008. Additionally, Mr. Hamilton will serve as chairman of the Company's audit committee. He will replace Judy Bruner, executive vice president of administration and chief financial officer of SanDisk Corporation, who resigned from the board
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
2. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
3. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
4. Vermillion Announces Effectiveness of Reverse Stock Split
5. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
8. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
9. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
10. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
11. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... September 01, 2014 The global ... million by 2019 from $1,070.7 million in 2014, ... to 2019. The global oligonucleotide synthesis market is ... applications, end users, and geography. The synthesized oligonucleotides ... rate in the oligonucleotide synthesis market during the ...
(Date:8/31/2014)... 2014 Market Research Report ... and in-depth research report on the Polyacrylamide ... including Polyacrylamide definition, classification, application, and industry ... This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic ...
(Date:8/29/2014)... electrons, but one of the most promising technologies for ... on light (photons) instead of electrons. First, it is ... single photons and control their direction. Researchers around the ... this control, but now scientists at the Niels Bohr ... photons emitted one at a time and in a ...
(Date:8/29/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the six months ended June 30, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... , Announced top-line results related to the eight ... enrolled in the Phase 2 iDEAL Study evaluating ...
Breaking Biology Technology:9.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4
... /PRNewswire/ -- The Nano Science and Technology Institute ... will take place May 3-7, 2009 at the George R. ... 12th year, the largest and most prominent Nanotechnology event is ... Micro and Bio technology executives, who will gather to promote ...
... CLINTON, N.J., Jan. 8 Ikaria Holdings, Inc. today ... present at the 27th Annual JPMorgan Healthcare Conference on ... The conference will be held January 12-15 at The ... Holdings, Inc. , Ikaria Holdings, Inc. is a ...
... /PRNewswire/ - Aegera Therapeutics Inc. announced today the ... Phase 2 study of AEG35156, their targeted antisense ... , The study, entitled "A Phase 2, Multicenter, ... Apoptosis (XIAP) Antisense AEG35156 Given In Combination With ...
Cached Biology Technology:NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 2NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 3NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 4Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference 2Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer 2
(Date:9/1/2014)... after birth, every child in the U.S. undergoes a ... conditions, including sickle cell disease. Thousands of children born ... many suffer and die from the disease each year. ... to at least some of those deaths. , ... in the lab of George Whitesides, the Woodford L. ...
(Date:9/1/2014)... basic building block of DNAcould initiate fragile X syndrome, the most ... The Journal of Cell Biology . , ... on the X chromosome called fragile X mental retardation 1 ... men carry a so-called premutation, in which a series of DNA ... slightly longer than normal. These repeats are prone to even further ...
(Date:9/1/2014)... to a life without light. They emit echolocation sounds and ... to obstacles or prey. In their brains, they have a ... by researchers at Technische Universitt Mnchen (TUM) has shown for ... factors. , Closer objects appear larger ... object, the number of activated neurons in its brain increases. ...
Breaking Biology News(10 mins):Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2
... June 1, 2010 -- The National Oceanic and Atmospheric ... of Miami (UM) to continue to lead its partnership ... (CIMAS). NOAA and UM scientists have worked ... of climate, hurricanes, and marine ecosystems along the southeastern ...
... Since the 1990s, a green fluorescent protein known simply as ... Northwest jellyfish, GFP allows scientists to visualize proteins inside of ... Two years ago, biologists who discovered and developed the protein ... work. However, using GFP as a fluorescent probe has ...
... viable due to aberrant chromosome distribution if they had ... German Cancer Research Center have investigated which genes are ... revealed that cancer cells rely on the tension ... Thus, proteins which maintain this tension are promising targets ...
Cached Biology News:NOAA selects University of Miami to lead major southeastern US cooperative institute 2NOAA selects University of Miami to lead major southeastern US cooperative institute 3MIT chemists design new way to fluorescently label proteins 2No relaxing for cancer cells 2
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... Major Science Smart Minis 150V power supply ... mini power supplies designed to meet most ... to use unit. The Minis 150V power ... The Minis Power Supply is designed for ...
Biology Products: